Dianthus Therapeutics (DNTH) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 144.6% versus a gain of 9.4%. Over five years, MIRM leads with a +371.0% price change compared with -21.2% for DNTH. Mirum Pharmaceuticals is the larger company by market cap ($5.24 billion vs $4.75 billion), about 1.1 times the size.
Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | MIRM |
|---|---|---|
| Share price | $84.88 | $80.64 |
| Market cap | $4.75B | $5.24B |
| 1-day change | -0.61% | +1.75% |
| YTD return | +105.97% | +2.09% |
| 1-year return | +144.61% | +9.36% |
| 5-year return | -21.17% | +371.03% |
| EPS (TTM) | $-4.24 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $521.31M |
| Revenue growth (YoY) | -67.35% | +54.74% |
| Net income (latest FY) | $-162.34M | $-23.36M |
| Operating margin | -8739.34% | -4.25% |
| Net margin | -7973.33% | -4.48% |
| 52-week high | $117.88 | $130.00 |
| 52-week low | $32.22 | $63.23 |
| Distance from 52-week high | -27.99% | -37.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.88% | +80.79% |
| Average volume | 825.33K | 693.63K |
| Shares outstanding | 55.93M | 64.93M |
| Employees | 92 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed MIRM by 135.3 percentage points over the past year.
- Mirum Pharmaceuticals is more profitable, keeping -4.5 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Mirum Pharmaceuticals grew revenue faster in its latest fiscal year (+54.74% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
DNTH vs MIRM FAQ
Which is bigger, Dianthus Therapeutics or Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.24B compared with $4.75B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or MIRM?
DNTH returned +144.61% over the past 12 months, compared with +9.36% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.